Does the degree of cell lesion in breast cancer after inductive chemotherapy have any prognostic value?

Acta Oncologica

Volumn 38, Issue 7, 1999, Pages 949-953

  Tomczykowski, Jacek ^a   Szubstarski, Franciszek ^a   Kurylcio, Lucjan ^a   Stanisławek, Andrzej ^a   Barycki, Jerzy ^a   Baranowski, Włodzimierz ^a  

^a MEDICAL UNIVERSITY OF LUBLIN   (Poland)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT;

ADJUVANT THERAPY; ARTICLE; BREAST CANCER; CANCER GRADING; CANCER SURVIVAL; CANCER SUSCEPTIBILITY; CELL DAMAGE; CONTROLLED STUDY; CORRELATION FUNCTION; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; PRIORITY JOURNAL; PROGNOSIS; SURVIVAL RATE;

ADULT; AGED; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; FEMALE; HUMANS; MIDDLE AGED; PROGNOSIS; SURVIVAL RATE;

EID: 0032758588     PISSN: 0284186X     EISSN: None     Source Type: Journal    
DOI: 10.1080/028418699432644     Document Type: Article

References (15)

1. 1. Brain E, Garrino C, Misset JL, Carbonero IG, Itzaki M, Cvitkovic E, et al. Long-term prognostic and predictive factors in 107 stage II/III breast cancer patients treated with anthracycline-based neoadjuvant chemotherapy. Br J Cancer 1997; 75: 1360-7.
2. 2. Chollet P, Charrier S, Brain E, et al. Clinical and pathological response to primary chemotherapy in operable breast cancer. Eur J Cancer 1997; 33: 862-6.
3. 3. Feldman LD, Hortobagyi GN, Budzar AU, Ames SC, Blumenschein GR. Pathological assessment of response to induction chemotherapy in breast cancer. Cancer Res 1986; 46: 2578-81.
4. 4. Ferriere JP, Assier I, Cure H, et al. Primary chemotherapy in breast cancer: correlation between tumor response and patient outcome. Am J Clin Oncol 1998; 21: 117-20.
5. 5. Honkoop AH, van Diest PJ, de Jong JS, et al. Prognostic role of clinical, pathological and biological characteristics in patients with locally advanced breast cancer. Br J Cancer 1998; 77: 621-6.
6. 6. Luboinski G, Nagadowska M, Pieńkowski T. Preoperative chemotherapy in primarily inoperable cancer of the breast. Eur J Surg Oncol 1991; 17: 603-7.
7. 7. Belembaogo E, Feillel V, Chollet P, Cure H, Verrelle P, Kwiatkowski F. Neoadjuvant chemotherapy in 126 operable breast cancers. Eur J Cancer 1992; 28A: 896-900.
8. 8. Bloom HJG, Richardson WW. Histological grading and prognosis in breast cancer. Br J Cancer 1957; 11: 359-77.
9. 9. Bonadonna G, Valagussa P, Brambilla C, Moliterni A, Zambetti M, Ferrari L. Adjuvant and neoadjuvant treatment of breast cancer with chemotherapy and/or endocrine therapy. Sem Oncol 1991; 18: 515-24.
10. 10. Colozza M, Gori S, Mosconi AM, et al. Induction chemotherapy with cisplatin, doxorubicin, and cyclophosphamide (CAP) in a combined modality approach for locally advanced and inflammatory breast cancer: long-term results. Am J Clin Oncol Cancer Clin Trials 1996; 19: 10-7.
11. 11. Ferrero JM, Namer M, Dufour JF, et al. A comparative study of 4 sequential first-line chemotherapy protocols in locally advanced breast cancer. Bull Cancer 1997; 84: 10-6.
12. 12. Chevallier B, Roche H, Olivier JP, Hurteloup P. Inflammatory breast cancer: intensive chemotherapy (FEC-BC) results in a high histologic complete response rate. Proc ASCO 1990; 9: 42-9.
13. 13. Chevallier B, Roche H, Olivier JP, Chollet P, Hurteloup P. Inflammatory breast cancer. Pilot study of intensive induction chemotherapy (FEC-HD) results in a high histologic response rate. Am J Clin Oncol 1993; 16: 223-8.
14. 14. Honkoop AH, Pinedo HM, de Jong JS, et al. Effects of chemotherapy on pathologic and biologic characteristic of locally advanced breast cancer. Am J Clin Pathol 1997; 107: 211-8.
15. 15. Marantz A, Pascoon G, Gerowich G, Litowska S. Neoadjuvant chemotherapy (NCT) in locally advanced breast cancer (LABC) stage III. Clinical and histopathological (HP) evaluation. Proc Annu Meet Am Soc Oncol 1989; 8A: 119.